Eczema
9 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Dermatitis
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Abrocitinib for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amlitelimab for eczema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATI-045 for eczema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dupilumab for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Lebrikizumab for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Optical Coherence Tomography + Reflectance confocal microscopy + DUPILUMAB for eczema | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Placebo + DUPILUMAB for eczema | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + LEBRIKIZUMAB for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.